Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
| Autor: | E A Demina |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Современная онкология, Vol 18, Iss 2, Pp 15-18 (2016) |
| Druh dokumentu: | article |
| ISSN: | 1815-1434 1815-1442 |
| Popis: | About 80% of patients can be cured using modern treatment of Hodgkin lymphoma, regardless of disease stage. However, the first chemotherapy line is not effective in 10-30% of patients, and these patients need to continue treatment. The investigation of targeted drugs associated with the specific activity in Berezovsky-Reed- Sternberg cells, opens up new prospects for the treatment of Hodgkin lymphoma. This article deals with the review of studies concerning the application of new drug brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|